Current status of adjuvant therapy for pancreatic cancer

Oncologist

Volumn 15, Issue 11, 2010, Pages 1205-1213

  Katz, Matthew H G ^a   Fleming, Jason B ^a   Lee, Jeffrey E ^a   Pisters, Peter W T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Chemoradiation; Chemotherapy; Neoadjuvant therapy; Pancreatic cancer; Pancreaticoduodenectomy

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ERLOTINIB; FLUOROURACIL; GEMCITABINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 78649934932     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0121     Document Type: Article

References (52)

1. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
2. Klinkenbijl JH, Jeekel J,Sahmoud T et al. Adjuvant radiotherapy and 5-flu-orouracil after curative resection of cancer of the pancreas and periampul-lary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999;230:776-782; discussion 782-774.
3. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007;297:267-277.
4. Smeenk HG, van Eijck CH, Hop WC et al. Long-term survival and meta-static pattern of pancreatic and periampullary cancer after adjuvant chemo-radiation or observation: Long-term results of EORTC trial 40891. Ann Surg 2007;246:734-740.
5. Katz MH, Wang H, Fleming JB et al. Long-term survival after multidisci-plinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009;16:836-847.
6. Bilimoria KY, Bentrem DJ, Ko CY et al. Multimodality therapy for pancreatic cancer in the U.S.: Utilization, outcomes, and the effect of hospital volume. Cancer 2007;110:1227-1234.
7. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-646.
8. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
9. Neoptolemos JP, Dunn JA, Stocken DD et-al Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 2001;358:1576-1585.
10. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemo-radiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
11. Evans DB, Hess KR, Pisters PW. ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas. Ann Surg 2002;236:694; author reply 694-696.
12. Corsini MM, Miller RC, Haddock MG et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005). J Clin Oncol 2008;26:3511-3516.
13. Herman JM, Swartz MJ, Hsu CC et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for duc-tal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008;26: 3503-3510.
14. Greco J, Castaldo E, Feurer I et al. Survival benefit with adjuvant radiation therapy in surgically resected pancreatic cancer [abstract]. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 19-21, 2007.
15. Merchant NB, Rymer J, Koehler EA et al. Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: Who really benefits? J Am Coll Surg 2009;208:829-838; discussion 838-841.
16. Neuhaus P, Riess H, PostS et al. CONKO-001: Final results ofthe randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. J Clin Oncol 2008;26(15 suppl):LBA4504.
17. Regine WF, Winter KA, Abrams RA etal Fluorouracilvsgemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008;299:1019-1026.
18. Neoptolemos JP, Buchler MW, Stocken DD et al. ESPAC-3(v2): A multi-center, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 2009;27(18 suppl): LBA4505.
19. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma. NCCN Clinical Practice Guidelines in Oncology 2009;1.2009. Available at http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf, accessed April 20, 2010.
20. Abrams RA, Lowy AM, O'Reilly EM et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: Expert consensus statement. Ann Surg Oncol 2009;16:1751-1756.
21. Aloia TA, Lee JE, Vauthey JN et al. Delayed recovery after pancreati-coduodenectomy: A major factor impairing the delivery of adjuvant therapy? J Am Coll Surg 2007;204:347-355.
22. Wayne JD, Abdalla EK, Wolff RA et al. Localized adenocarcinoma of the pancreas: The rationale for preoperative chemoradiation. The Oncologist 2002;7:34-45.
23. Cheng TY, Sheth K, White RR et al. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol 2006;13:66-74.
24. Sasson AR, Wetherington RW, Hoffman JP et al. Neoadjuvant chemora-diotherapy for adenocarcinomaof the pancreas: Analysisof histopathology and outcome. Int J Gastrointest Cancer 2003;34:121-128.
25. White RR, Xie HB, Gottfried MR et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 2005;12:214-221.
26. Pingpank JF, Hoffman JP, Ross EA et al. Effect of preoperative chemora-diotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001;5:121-130.
27. Heinrich S, Schäfer M, Weber A et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: Results of a prospective phase II trial. Ann Surg 2008;248:1014-1022.
28. Breslin TM, Hess KR, Harbison DB et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration. Ann Surg Oncol 2001;8:123-132.
29. Greer SE, Pipas JM, Sutton JE et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 2008;206:451-457.
30. Evans DB, Rich TA, Byrd DR et al. Preoperative chemoradiation and pan-creaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127:1335-1339.
31. Pisters PW, Abbruzzese JL, Janjan NA et al. Rapid-fractionation preoper-ative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998; 16:3843-3850.
32. Pisters PW, Wolff RA, Janjan NA et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarci-noma: Toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002;20:2537-2544.
33. Evans DB, Varadhachary GR, Crane CH et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3496-3502.
34. Varadhachary GR, Wolff RA, Crane CH et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resect-able adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26: 3487-3495.
35. White RR, Hurwitz HI, Morse MA et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001;8:758-765.
36. Heinrich S, Pestalozzi BC, Schäfer M et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resect-able adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26: 2526-2531.
37. Talamonti MS, Small W Jr, Mulcahy MF et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006;13:150-158.
38. Mornex F, Girard N, Scoazec JY et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cis-platin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 phase II trial. Int J Radiat Oncol Biol Phys 2006; 65:1471-1478.
39. Hoffman JP, Lipsitz S, Pisansky T et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable ad-enocarcinoma of the pancreas: An Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:317-323.
40. Stessin AM, Meyer JE, Sherr DL. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: An analysis of data from the Surveillance, Epidemiology, and End Results (SEER) registry. Int J Radiat Oncol Biol Phys 2008;72:1128-1133.
41. Callery MP, Chang KJ, Fishman EK et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 2009;16:1727-1733.
42. Katz MH, Pisters PW, Evans DB et al. Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 2008;206:833-846; discussion 846-848.
43. Varadhachary GR, Tamm EP, Abbruzzese JL et al. Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13:1035-1046.
44. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
45. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevaci-zumab in combination with gemcitabine and erlotinib in patients with met-astatic pancreatic cancer. J Clin Oncol 2009;27:2231-2237.
46. Philip PA, Benedetti J, Fenoglio CJ et al. Phase III study of gemcitabine plus ceutiximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. J Clin Oncol 2007;25:(18 suppl):LBA4509.
47. Kindler HL, Niedzwiecki D, Hollis D et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: A preliminary analysis of Cancer and Leukemia Group B. J Clin Oncol 2007;25(18 suppl):LBA4508.
48. Pfizer Inc. Pfizer Discontinues Axitinib Pancreatic Cancer Trial [press release]. Available at http://mediaroom.pfizer.com/portal/site/pfizer/ index.jsp?ndmViewId=news_view&ndmConfigId = 1006615&newsId = 20090202006193&newsLang = en, accessed April 20, 2010.
49. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-167.
50. Exocrine pancreas. In: Greene FL, Page DL, Fleming ID et al., eds. AJCC Cancer Staging Manual. Chicago: Springer, 2002:157-164.
51. Katz MH, Varadhachary GR, Fleming JB et al Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 2010;17:1794-1801.
52. Katz MH, Merchant NB, Brower S et al. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: Results from the ACOSOG Z5031 trial. Ann Surg Oncol 2010 Sep 1 [Epub ahead of print].